Table 2.
Clinicopathological characteristics of different MRS risk groups.
| Characteristics | Cohort 1 (n = 110) | p-value | Cohort 2 (n = 55) | p-value | ||
|---|---|---|---|---|---|---|
| MRS low | MRS high | MRS low | MRS high | |||
| Age (years) | ||||||
| ≤48 | 33 | 13 | 0.504 | 20 | 9 | 0.215 |
| >48 | 50 | 14 | 22 | 4 | ||
| Gender | ||||||
| Female | 13 | 2 | 0.351 | 4 | 0 | 0.562 |
| Male | 70 | 25 | 38 | 13 | ||
| HBsAg | ||||||
| Negative | 9 | 4 | 0.732 | 7 | 0 | 0.179 |
| Positive | 74 | 23 | 35 | 13 | ||
| AFP (ng/mL) | ||||||
| ≤25 | 24 | 10 | 0.476 | 13 | 2 | 0.477 |
| >25 | 59 | 17 | 29 | 11 | ||
| ALT (U/L) | ||||||
| ≤40 | 44 | 14 | 1.000 | 30 | 8 | 0.511 |
| >40 | 39 | 13 | 12 | 5 | ||
| Tumor size (cm) | ||||||
| ≤5 | 33 | 12 | 0.822 | 18 | 3 | 0.328 |
| >5 | 50 | 15 | 24 | 10 | ||
| Child–Pugh class | ||||||
| A | 80 | 27 | 1.000 | 42 | 12 | 0.236 |
| B–C | 3 | 0 | 0 | 1 | ||
| Tumor number | ||||||
| Single | 56 | 19 | 1.000 | 31 | 9 | 0.734 |
| Multiple | 27 | 9 | 11 | 4 | ||
| Vascular invasion | ||||||
| No | 75 | 21 | 0.103 | 37 | 7 | 0.014* |
| Yes | 8 | 6 | 5 | 6 | ||
| BCLC stage | ||||||
| 0–A | 47 | 12 | 0.374 | 28 | 5 | 0.106 |
| B–C | 36 | 15 | 14 | 8 | ||
p-values were analyzed by χ2 test or Fisher’s exact test, as appropriate.
HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; ALT, alanine aminotransferase; BCLC, Barcelona Clinic Liver Cancer. Data are presented as number of patients.